Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin inBRAFwild-type melanoma-Reference-Cited by-同舟云学术

Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin inBRAFwild-type melanoma

Published:2014-02-21 Issue:3 Volume:27 Page:465-478
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res.

Author:

Rebecca Vito W.¹,Massaro Renato R.²,Fedorenko Inna V.¹,Sondak Vernon K.³,Anderson Alexander R. A.⁴,Kim Eunjung⁴,Amaravadi Ravi K.⁵,Maria-Engler Silvya S.²,Messina Jane L.³⁶,Gibney Geoffrey T.³,Kudchadkar Ragini R.³,Smalley Keiran S. M.¹³

Affiliation:

1. Department of Molecular Oncology; The Moffitt Cancer Center and Research Institute; Tampa FL USA

2. Department of Clinical Analysis and Toxicology; School of Pharmaceutical Sciences; University of Sao Paulo; Sao Paulo Brazil

3. Department of Cutaneous Oncology; The Moffitt Cancer Center and Research Institute; Tampa FL USA

4. Department of Integrated Mathematical Oncology; The Moffitt Cancer Center and Research Institute; Tampa FL USA

5. The Abramson Cancer Center; University of Pennsylvania; Philadelphia PA USA

6. Department of Pathology and Cell Biology; University of South Florida College of Medicine; Tampa FL USA

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12227/fullpdf

Reference53 articles.

1. Algazy , K.M. Schuchter , L. Demichele , A.M. David , V.J. Torigian , D.A. Chang , C.Y. Redlinger , M. Davis , L.E. O'dwyer , P.J. Amaravadi , R. 2011 Combined mTOR and autophagy inhibition: Phase I trial of temsirolimus and hydroxychloroquine in patients with advanced solid tumors

2. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study;Ascierto;Lancet Oncol.,2013

3. Targeted deletion of autophagy-related 5 (atg5) impairs adipogenesis in a cellular model and in mice;Baerga;Autophagy,2009

4. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice;Bedogni;Cancer Res.,2004

5. Melanoma genome sequencing reveals frequent PREX2 mutations;Berger;Nature,2012

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance;Cells;2024-01-26

2. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma;Oncogene;2023-12-08

3. Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis;Frontiers in Cell and Developmental Biology;2023-04-26

4. ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous Melanoma;2023-04-20

5. Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma;Journal of Medicinal Chemistry;2023-03-24